Cargando…

Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases—Is It the Future?

The increasing prevalence of cardiovascular disease and concomitant chronic kidney disease among the aging populations is responsible for considerable growth of mortality. Additionally, frequent, prolonged hospitalizations and long-term treatment generates progressive decline in bodily functions as...

Descripción completa

Detalles Bibliográficos
Autores principales: Czajkowska, Katarzyna, Zbroch, Edyta, Bielach-Bazyluk, Angelika, Mitrosz, Katarzyna, Bujno, Elzbieta, Kakareko, Katarzyna, Rydzewska-Rosolowska, Alicja, Hryszko, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867137/
https://www.ncbi.nlm.nih.gov/pubmed/33540505
http://dx.doi.org/10.3390/jcm10030524
_version_ 1783648234356342784
author Czajkowska, Katarzyna
Zbroch, Edyta
Bielach-Bazyluk, Angelika
Mitrosz, Katarzyna
Bujno, Elzbieta
Kakareko, Katarzyna
Rydzewska-Rosolowska, Alicja
Hryszko, Tomasz
author_facet Czajkowska, Katarzyna
Zbroch, Edyta
Bielach-Bazyluk, Angelika
Mitrosz, Katarzyna
Bujno, Elzbieta
Kakareko, Katarzyna
Rydzewska-Rosolowska, Alicja
Hryszko, Tomasz
author_sort Czajkowska, Katarzyna
collection PubMed
description The increasing prevalence of cardiovascular disease and concomitant chronic kidney disease among the aging populations is responsible for considerable growth of mortality. Additionally, frequent, prolonged hospitalizations and long-term treatment generates progressive decline in bodily functions as well as substantial public health and economic burden. Accessibility to easy, non-invasive prognostic markers able to detect patients at risk of cardiovascular events may improve effective therapy and mitigate disease progression. Moreover, an early diagnosis allows time for implementation of prophylactic and educational programs that may result in decreased morbidity, improved quality of life and reduced public health expenditure. One of the promising candidates for a novel cardiovascular biomarker is mid-regional proadrenomedullin, a derivative of adrenomedullin. Adrenomedullin is a peptide hormone known for its vasodilatory, antioxidant, antiapoptotic and antifibrotic effects. A remarkable advantage of mid-regional proadrenomedullin is its longer half-life which is a prerequisite for plasma measurements. These review aims to discuss the importance of mid-regional proadrenomedullin with reference to its usefulness as a biomarker of increased cardiovascular risk and kidney disease progression.
format Online
Article
Text
id pubmed-7867137
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78671372021-02-07 Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases—Is It the Future? Czajkowska, Katarzyna Zbroch, Edyta Bielach-Bazyluk, Angelika Mitrosz, Katarzyna Bujno, Elzbieta Kakareko, Katarzyna Rydzewska-Rosolowska, Alicja Hryszko, Tomasz J Clin Med Review The increasing prevalence of cardiovascular disease and concomitant chronic kidney disease among the aging populations is responsible for considerable growth of mortality. Additionally, frequent, prolonged hospitalizations and long-term treatment generates progressive decline in bodily functions as well as substantial public health and economic burden. Accessibility to easy, non-invasive prognostic markers able to detect patients at risk of cardiovascular events may improve effective therapy and mitigate disease progression. Moreover, an early diagnosis allows time for implementation of prophylactic and educational programs that may result in decreased morbidity, improved quality of life and reduced public health expenditure. One of the promising candidates for a novel cardiovascular biomarker is mid-regional proadrenomedullin, a derivative of adrenomedullin. Adrenomedullin is a peptide hormone known for its vasodilatory, antioxidant, antiapoptotic and antifibrotic effects. A remarkable advantage of mid-regional proadrenomedullin is its longer half-life which is a prerequisite for plasma measurements. These review aims to discuss the importance of mid-regional proadrenomedullin with reference to its usefulness as a biomarker of increased cardiovascular risk and kidney disease progression. MDPI 2021-02-02 /pmc/articles/PMC7867137/ /pubmed/33540505 http://dx.doi.org/10.3390/jcm10030524 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Czajkowska, Katarzyna
Zbroch, Edyta
Bielach-Bazyluk, Angelika
Mitrosz, Katarzyna
Bujno, Elzbieta
Kakareko, Katarzyna
Rydzewska-Rosolowska, Alicja
Hryszko, Tomasz
Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases—Is It the Future?
title Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases—Is It the Future?
title_full Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases—Is It the Future?
title_fullStr Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases—Is It the Future?
title_full_unstemmed Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases—Is It the Future?
title_short Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases—Is It the Future?
title_sort mid-regional proadrenomedullin as a new biomarker of kidney and cardiovascular diseases—is it the future?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867137/
https://www.ncbi.nlm.nih.gov/pubmed/33540505
http://dx.doi.org/10.3390/jcm10030524
work_keys_str_mv AT czajkowskakatarzyna midregionalproadrenomedullinasanewbiomarkerofkidneyandcardiovasculardiseasesisitthefuture
AT zbrochedyta midregionalproadrenomedullinasanewbiomarkerofkidneyandcardiovasculardiseasesisitthefuture
AT bielachbazylukangelika midregionalproadrenomedullinasanewbiomarkerofkidneyandcardiovasculardiseasesisitthefuture
AT mitroszkatarzyna midregionalproadrenomedullinasanewbiomarkerofkidneyandcardiovasculardiseasesisitthefuture
AT bujnoelzbieta midregionalproadrenomedullinasanewbiomarkerofkidneyandcardiovasculardiseasesisitthefuture
AT kakarekokatarzyna midregionalproadrenomedullinasanewbiomarkerofkidneyandcardiovasculardiseasesisitthefuture
AT rydzewskarosolowskaalicja midregionalproadrenomedullinasanewbiomarkerofkidneyandcardiovasculardiseasesisitthefuture
AT hryszkotomasz midregionalproadrenomedullinasanewbiomarkerofkidneyandcardiovasculardiseasesisitthefuture